Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Endocrinology
•
Bone and Calcium Disorders
•
Primary Care
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
Answer from: at Academic Institution
My practice has been that after 2-3 years of denosumab, I wait 6 months and then start zoledronic acid.
Sign in or Register to read more
Answer from: at Community Practice
Six months after the last injection.
Sign in or Register to read more
Answer from: at Community Practice
Yes, 6 months after last Prolia shot. I give 2 doses of Zoledronic 1 year apart and then consider drug holiday based on the DEXA report.
Sign in or Register to read more
24261
24290
25967
Related Questions
Would you consider PTH analogue in a patient with mildly elevated PTH?
How do you manage osteoporosis treatment following parathyroidectomy for primary hyperparathyroidism?
Would you stop denosumab in a patient with chronic kidney disease if they develop asymptomatic hypocalcemia after the injection?
Do you routinely use anti-resorptive medications in patients who have osteoporosis and longstanding hypoparathyroidism?
Would you continue Forteo treatment past the recommended 2 years if T scores remain low and procollagen (P1NP) is elevated and if so, how would you monitor response?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
Would you ever consider retreatment with an antiresorptive medication in a patient with a remote history of atypical fracture attributed to an oral bisphosphonate?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
How do you approach management of osteoporosis in patients post lung transplant?
Do you recommend adjusting the duration of a drug holiday based on the specific bisphosphonate used when treating osteoporosis?